Results 141 to 150 of about 459,313 (206)

DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial. [PDF]

ESMO Gastrointest Oncol
Gordon A, Cartwright E, Tran A, Crux R, Turkes F, Smyth E, Smith A, Manalang I, Rana I, Kohoutova D, Johnston E, Dunlop A, Ul-Islam MS, Falk S, Sita-Lumsden A, Rao S, Starling N, Chau I, Cunningham D.   +18 more
europepmc   +1 more source

Canadian healthcare professionals' attitudes towards climate change and the environmental impact of inhalers. [PDF]

J Clim Chang Health
Butler SJ, Digby GC, Roy C, Tse SM, Sajwani S, Hubick J, McCoy C, Lam I, Singer A, Kaplan A, Leek E, Walji S, Stoynova V, Penz E, Gupta S.   +14 more
europepmc   +1 more source

Persistent refractory hypercapnia following tracheostomy decannulation in a patient with brainstem hemorrhage: a case report. [PDF]

Front Rehabil Sci
Deng Y, Wang F, Li Y, Xue D, Liang J, Chen H, Xie W, Fu B, Hao M.   +8 more
europepmc   +1 more source

Pulsed field ablation as first-line therapy for the treatment of atrial fibrillation: a FARADISE sub-analysis. [PDF]

Europace
García-Bolao I, Szegedi N, Vijgen J, Széplaki G, Russo AD, Efremidis M, Willems S, Haqqani H, Gandjbakhch E, Fiala M, Andrikopoulos G, Luik A, Defaye P, Ouss A, Lugenbiel P, Balsam P, Bulava A, Gramlich M, Eckardt L, Hussin A, Martin CA, Duytschaever M, Osca J, Elfstrum A, Cielen N, Johnson M, Auricchio A, Boersma LVA, FARADISE Investigators.   +28 more
europepmc   +1 more source

Efficacy and biomarker analysis for nivolumab in cancer of unknown primary: results from an investigator-initiated expanded access program. [PDF]

Int J Clin Oncol
Tanizaki J, Yonemori K, Takiguchi Y, Akiyoshi K, Komine K, Onozawa Y, Sato M, Hirata K, Onoe T, Ohkuma R, Horita Y, Minami H, Honda K, Suyama K, Ito A, Chiba Y, Watanabe H, Togashi Y, Sakai K, Nishio K, Nakagawa K, Hayashi H.   +21 more
europepmc   +1 more source

Beyond pharmacology: The mediating role of expectations in the experience of side effects in anxious patients treated with secukinumab. [PDF]

Brain Behav Immun Health
Mühlhaus S, Krefting F, Bese D, Schedlowski M, Sondermann W, Hölsken S.   +5 more
europepmc   +1 more source

Paying in the dark: third-party administrator fees and the limits of employer cost control in self-insured health plans. [PDF]

Health Aff Sch
Buttorff C, Rasmussen PW, Bhandarkar M, Shiferaw M, Duffy EL.   +4 more
europepmc   +1 more source

<i>ESR1</i> Y537S Detected in a Brain Metastasis but Not in Plasma ctDNA in HR+/HER2-Low Metastatic Breast Cancer: A Case Report. [PDF]

Curr Oncol
Nègre A, Seguin L, Géraud Cremieux A, Viret F, Tallet A, Popovici C, Gonçalves A, de Nonneville A.   +7 more
europepmc   +1 more source

Rhode Island Affordability Standards and Hospital-Affiliated Clinicians' Professional Fees.

JAMA Netw Open
Murray RC, Whaley CM, Ryan AM.
europepmc   +1 more source